神经妥乐平联合羟考酮控释片治疗癌性神经病理性疼痛的临床效果评价

摘要

Objective To study the clinical effect of neurotropin combined with controlled-release oxycodone tablets for neuropathic cancer pain.Methods 86 cases of neuropathic cancer pain patients with VAS score ＞ 4 were randomly divided into 2 groups,the control group and the treatment group,43 cases in each group.To control group received placebo and controlled-release oxycodone tablets,the treatment group received neurotropin combined with controlled-release oxycodone tablets.VAS score,SAS scores,pain relief after treatment,7 d and 14 d after the outbreak of pain treatment and controlled-release oxycodone tablets of the 2 groups before and after treatment were compared.Results After treatment,the VAS score of the experimental group was (0.96 ± 1.08) points,SAS score was(36.69 ±8.45),which were significantly lower than those of the control group (3.01 ±1.29),(48.56 ± 10.27),there had statistically significant difference (P ＜ 0.05);The overall situation of pain relief in the experimental group was obviously better than the control group,the pain relief rate (95.35％) was significantly higher than that of the control group (53.49％),there had statistically significant difference (P ＜ 0.05);Outbreak of pain in the experimental group at day 14 was (1.72 ± 0.95) times/d,controlled-release oxycodone tablets daily dose was (80.76 ± 20.79) mg/d,which was obviously better than that of the control group (2.21 ± 1.24) times/d,(101.99 ± 23.56) mg/d,there had statistically significant difference (P ＜ 0.05).Conclusion Neurotropin combined with controlled-release oxycodone tablets can relieve neuropathic cancer pain,it has a better clinical therapeutic effect.%目的 探讨癌性神经病理性疼痛患者使用神经妥乐平+羟考酮控释片治疗后的临床效果.方法 选取VAS评分＞4分的癌性神经病理性疼痛患者86例,并按数字表法随机分为对照组与试验组两组,每组均43例.对照组予以安慰剂+羟考酮控释片的治疗方案,试验组则实施神经妥平乐+羟考酮控释片的治疗措施.分析对比两组患者治疗前后VAS评分、SAS评分、治疗后疼痛缓解情况、治疗7d及14 d后爆发痛发作情况及羟考酮控释片服用情况.结果 经过治疗后,试验组患者VAS评分为(0.96±1.08)分、SAS评分为(36.69 ±8.45)分,均明显低于对照组的(3.01±1.29)分、(48.56±10.27)分,差异有统计学意义(P＜0.05);试验组患者整体疼痛缓解情况明显优于对照组,疼痛缓解率(95.35％)明显高于对照组的(53.49％),组间对比有统计学上有意义(P＜0.05);治疗14 d时,试验组爆发痛发作次数为(1.72±0.95)次/d、羟考酮控释片日均服用量为(80.76±20.79) mg/d,均明显优于对照组[(2.21±1.24)次/d、(101.99±23.56)mg/d],有统计学意义(P＜0.05).结论 神经妥乐平联合羟考酮控释片联合治疗,可缓解肿瘤患者的癌性神经病理性疼痛,临床治疗效果较优.